Gender-Identity Policy: Youth Medical Care and Sports Eligibility

What the evidence says

The largest concentration of evidence on medical interventions covers mental-health outcomes of puberty blockers (PBs) and gender-affirming hormones (GAHs) in transgender and nonbinary youth, and it points toward decreased depression and decreased suicidality. An adjusted cohort study found 60% lower odds of moderate-to-severe depression (aOR 0.40, 95% CI 0.17–0.95) and 73% lower odds of suicidality or self-harm (aOR 0.27, 95% CI 0.11–0.65) among youths who had initiated PBs or GAHs versus those who had not. Smaller, unadjusted clinical-cohort studies point the same direction: adolescents in the Netherlands (n=70) showed decreased depression after roughly two years of puberty suppression; adolescents in the United States (n=47) showed decreased suicidality after roughly one year of GAH therapy; and adolescents in Spain (n=23) showed decreased anxiety and depression after one year. Anxiety specifically does not carry the same agreement across sources — see "Where the evidence splits" below.

A second cluster covers the biological and developmental basis of gender dysphoria in children. One source describes clinical outcomes as heterogeneous — dysphoria "may either disappear at puberty or persist into adult life" — and reports gender identity as biologically determined during prenatal development, not reversible by postnatal environmental conditions. A twin study cited in the same source found an additive genetic component accounting for 62% of variance in clinically significant gender dysphoria (157 twin pairs, 2.3% prevalence of clinically significant dysphoria in that sample). Reported population prevalence of gender dysphoria in youth is low: 0.005–0.014% in natal males and 0.002–0.0003% in natal females. Separately, a survey of 315 Chilean transgender individuals found 50.1% reported recognizing gender incongruence between ages 0 and 18, and 7.6% before age 12.

A third cluster covers access to care, and it is consistently one-directional: financial cost, parental-consent requirements for minors, provider discomfort or reluctance to prescribe hormones, gatekeeping of non-binary patients by mental-health providers, and gaps in provider knowledge of transgender-specific care all decrease access to gender-affirming care, according to the sources gathered here. Financial cost was reported as the most commonly cited barrier across hormone therapy, top surgery, and bottom surgery in one qualitative survey, though no participant percentage was given. Despite these barriers, 61.3% of surveyed transgender and gender-nonconforming individuals in that same survey had obtained hormone therapy.

A fourth cluster covers physical health correlates. Early-pubertal transgender youth initiating GnRH agonists show decreased bone mineral density relative to sex-matched reference standards (except at hip sites in natal females), with severely low bone density (Z-score ≤ −2) in 30% of natal-male and 13% of natal-female youth, against 2.3% expected in a normal distribution; this population also reports suboptimal daily calcium intake (613 mg/day versus a 1,300 mg/day recommendation) and 15% prevalence of vitamin D insufficiency. Transgender and gender-diverse (TGD) youth also present to pediatric pain clinics at higher rates than expected (34% in one clinical sample) and report pain interfering with daily functioning more often than cisgender peers (30% versus 16% of cisgender girls and 8% of cisgender boys in one Swedish school survey); TGD youth who reported discrimination showed roughly twice the prevalence of chronic pain (20.2% versus 7.0%) as those who did not.

A fifth cluster covers athletic performance after feminizing hormone therapy in adults, not youth specifically — the sports-performance sources here do not report youth-specific data. Following feminizing hormone therapy, pushup and sit-up performance in transgender women declines toward cisgender women's levels within two years, while a relative advantage in 1.5-mile running remains evident after two years. Hemoglobin and hematocrit decline to the cisgender female range within three to four months, while lean body mass, muscle cross-sectional area, and strength often remain higher than cisgender women's even after 36 months. Different fitness indicators change at different rates after starting hormone therapy. Separately, NCAA and IOC eligibility policies restrict women's-category competition to athletes meeting sex-assigned-at-birth or biological-female screening criteria.

Where the evidence splits

The effect of hormone therapy or puberty blockers on anxiety is contested. An adjusted cohort study of transgender and nonbinary youth found no measured association between receipt of puberty blockers or gender-affirming hormones and moderate-or-severe anxiety (aOR 1.01, 95% CI 0.41–2.51), after adjustment for temporal trends and potential confounders. A smaller, unadjusted clinical cohort in Spain (n=23) reported decreased anxiety after one year of gender-affirming hormone therapy, and a separate review states that gender-affirming hormone therapy "leads to reductions in anxiety, depression, and suicidality" without giving effect sizes. The sources themselves point to a design difference that may explain the split: the null result comes from a larger sample with adjustment for confounders and temporal trends, while the positive results come from small, unadjusted before/after clinical cohorts (n=23) or an unspecified multi-study review.

Thresholds and dose-response

A bone-density cutoff is explicitly established: among early-pubertal transgender youth initiating GnRH agonists, a Z-score below −2 (defined as low bone mineral density) occurred in 30% of natal-male youth and 13% of natal-female youth, compared with 2.3% expected in a normal distribution.

A time-based dose-response is reported for two physiological measure sets after starting feminizing hormone therapy in transgender women: hemoglobin and hematocrit decline to the cisgender female range within three to four months, while lean body mass, muscle cross-sectional area, and strength often remain higher than cisgender women's even after 36 months — the two measure sets converge toward cisgender-female reference ranges on different timescales.

A second time-based pattern is reported for athletic performance: pushup and sit-up performance approaches cisgender women's levels within two years of feminizing hormone therapy, while a relative advantage in 1.5-mile running remains evident after the same two-year mark.

Open empirical questions

• What are the outcomes of pediatric gender-affirming care beyond the roughly 1–2-year follow-up windows reported here — no source in this set reports longer-term (multi-year to adult) outcomes.
• Do the reported financial, parental-consent, and provider-related barriers cause reduced treatment-seeking or care utilization, or only correlate with it — the cited studies are qualitative/descriptive and do not establish a causal link.
• Does the bone-density deficit observed in early-pubertal transgender youth on GnRH agonists persist, worsen, or recover with continued treatment or after treatment ends — the source describes this as unresolved.
• Do the reported athletic-performance patterns in adult transgender women (pushup/sit-up convergence, hematologic normalization, persistent strength differences) apply to youth athletes specifically — no youth-specific athletic-performance data appear in these sources.